Cargando…

Antibiotics or probiotics as preventive measures against ventilator-associated pneumonia: a literature review

INTRODUCTION: Mechanically ventilated critically ill patients frequently develop ventilator-associated pneumonia (VAP), a life-threatening complication. Proposed preventive measures against VAP include, but are not restricted to, selective decontamination of the digestive tract (SDD), selective orop...

Descripción completa

Detalles Bibliográficos
Autores principales: Schultz, Marcus J, Haas, Lenneke E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3222052/
https://www.ncbi.nlm.nih.gov/pubmed/21232110
http://dx.doi.org/10.1186/cc9963
_version_ 1782217164348981248
author Schultz, Marcus J
Haas, Lenneke E
author_facet Schultz, Marcus J
Haas, Lenneke E
author_sort Schultz, Marcus J
collection PubMed
description INTRODUCTION: Mechanically ventilated critically ill patients frequently develop ventilator-associated pneumonia (VAP), a life-threatening complication. Proposed preventive measures against VAP include, but are not restricted to, selective decontamination of the digestive tract (SDD), selective oropharyngeal decontamination (SOD) and the use of probiotics. Probiotics are live bacteria that could have beneficial effects on the host by altering gastrointestinal flora. Similar to SDD and SOD, a prescription of probiotics aims at the prevention of secondary colonization of the upper and/or lower digestive tract. METHODS: We performed a literature review to describe the differences and similarities between SDD/SOD and probiotic preventive strategies, focusing on (a) efficacy, (b) risks, and (c) the routing of these strategies. RESULTS: Reductions in the incidence of VAP have been achieved with SDD and SOD. Two large randomized controlled trials even showed reduced mortality with these preventive strategies. Randomized controlled trials of probiotic strategies also showed a reduction of the incidence of VAP, but trials were too small to draw firm conclusions. Preventive strategies with antibiotics and probiotics may be limited due to the risk of emerging resistance to the locally applied antibiotics and the risk of probiotic-related infections, respectively. The majority of trials of SDD and SOD did not exhaustively address the issue of emerging resistance. Likewise, trials of probiotic strategies did not adequately address the risk of colonization with probiotics and probiotic-related infection. In studies of SDD and SOD the preventive strategy aimed at decontamination of the oral cavity, throat, stomach and intestines, and the oral cavity and throat, respectively. In the vast majority of studies of probiotic therapy the preventive strategy aimed at decontamination of the stomach and intestines. CONCLUSIONS: Prophylactic use of antibiotics in critically ill patients is effective in reducing the incidence of VAP. Probiotic strategies deserve consideration in future well-powered trials. Future studies are needed to determine if preventive antibiotic and probiotic strategies are safe with regard to development of antibiotic resistance and probiotic infections. It should be determined whether the efficacy of probiotics improves when these agents are provided to the mouth and the intestines simultaneously.
format Online
Article
Text
id pubmed-3222052
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-32220522011-11-22 Antibiotics or probiotics as preventive measures against ventilator-associated pneumonia: a literature review Schultz, Marcus J Haas, Lenneke E Crit Care Research INTRODUCTION: Mechanically ventilated critically ill patients frequently develop ventilator-associated pneumonia (VAP), a life-threatening complication. Proposed preventive measures against VAP include, but are not restricted to, selective decontamination of the digestive tract (SDD), selective oropharyngeal decontamination (SOD) and the use of probiotics. Probiotics are live bacteria that could have beneficial effects on the host by altering gastrointestinal flora. Similar to SDD and SOD, a prescription of probiotics aims at the prevention of secondary colonization of the upper and/or lower digestive tract. METHODS: We performed a literature review to describe the differences and similarities between SDD/SOD and probiotic preventive strategies, focusing on (a) efficacy, (b) risks, and (c) the routing of these strategies. RESULTS: Reductions in the incidence of VAP have been achieved with SDD and SOD. Two large randomized controlled trials even showed reduced mortality with these preventive strategies. Randomized controlled trials of probiotic strategies also showed a reduction of the incidence of VAP, but trials were too small to draw firm conclusions. Preventive strategies with antibiotics and probiotics may be limited due to the risk of emerging resistance to the locally applied antibiotics and the risk of probiotic-related infections, respectively. The majority of trials of SDD and SOD did not exhaustively address the issue of emerging resistance. Likewise, trials of probiotic strategies did not adequately address the risk of colonization with probiotics and probiotic-related infection. In studies of SDD and SOD the preventive strategy aimed at decontamination of the oral cavity, throat, stomach and intestines, and the oral cavity and throat, respectively. In the vast majority of studies of probiotic therapy the preventive strategy aimed at decontamination of the stomach and intestines. CONCLUSIONS: Prophylactic use of antibiotics in critically ill patients is effective in reducing the incidence of VAP. Probiotic strategies deserve consideration in future well-powered trials. Future studies are needed to determine if preventive antibiotic and probiotic strategies are safe with regard to development of antibiotic resistance and probiotic infections. It should be determined whether the efficacy of probiotics improves when these agents are provided to the mouth and the intestines simultaneously. BioMed Central 2011 2011-01-13 /pmc/articles/PMC3222052/ /pubmed/21232110 http://dx.doi.org/10.1186/cc9963 Text en Copyright ©2011 Schultz et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Schultz, Marcus J
Haas, Lenneke E
Antibiotics or probiotics as preventive measures against ventilator-associated pneumonia: a literature review
title Antibiotics or probiotics as preventive measures against ventilator-associated pneumonia: a literature review
title_full Antibiotics or probiotics as preventive measures against ventilator-associated pneumonia: a literature review
title_fullStr Antibiotics or probiotics as preventive measures against ventilator-associated pneumonia: a literature review
title_full_unstemmed Antibiotics or probiotics as preventive measures against ventilator-associated pneumonia: a literature review
title_short Antibiotics or probiotics as preventive measures against ventilator-associated pneumonia: a literature review
title_sort antibiotics or probiotics as preventive measures against ventilator-associated pneumonia: a literature review
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3222052/
https://www.ncbi.nlm.nih.gov/pubmed/21232110
http://dx.doi.org/10.1186/cc9963
work_keys_str_mv AT schultzmarcusj antibioticsorprobioticsaspreventivemeasuresagainstventilatorassociatedpneumoniaaliteraturereview
AT haaslennekee antibioticsorprobioticsaspreventivemeasuresagainstventilatorassociatedpneumoniaaliteraturereview